Managing Co-Morbidities in HIV Infected Patients: A Case-Based Approach
Track:
Educational Sessions
Program Code: 235-L02
Date: Tuesday, December 9, 2008
Time: 3:00 PM to 5:00 PM EST
Location:
S230B
MEETING PLANNING ASSOCIATE:
Click the plus sign to see more detailed information about each speaker.
Kathleen Melbourne, PharmD, Associate Director, Medical Scientist, Gilead Sciences
Dr. Melbourne is an Associate Director and HIV Medical Scientist (covering Northeast US) at Gilead Sciences. She began her employment with Gilead Sciences in May 2006. She has been on the faculty of the University of Rhode Island College of Pharmacy since 1998, where she is currently a Clinical Associate Professor of Pharmacy. Dr. Melbourne received her BS and PharmD from the University of Rhode Island College of Pharmacy in 1993 and 1995, respectively. She completed an ASHP-accredited Pharmacy Practice Residency at the University of Pittsburgh Medical Center in 1996. In 1997, she completed an Infectious Disease/HIV Pharmacotherapy Fellowship at the Anti-infective Pharmacology Research Unit, affiliated with the University of Rhode Island College of Pharmacy and Brown University Medical School. From 1997-2006, Dr. Melbourne was the Director of the Pharmacy Care Management Program at Coastal Medical, a private medical group consisting of 16 physicians offices located throughout Rhode Island. During her tenure at Coastal Medical, Dr. Melbourne led the implementation of collaborative pharmacy services throughout the primary care network of Coastal Medical, directed a Pharmacy Residency Program, conducted clinical studies measuring the impact of clinical pharmacy services on patient outcomes, precepted PharmD students from the URI College of Pharmacy, and carried on a clinical practice involving both HIV-infected patients and patients with multiple chronic illnesses. Dr. Melbourne's work at Coastal Medical was recognized in 2000 by the American Pharmacists Association Foundation's Quality Center. Currently, her research and clinical focus is on the metabolic and morphologic changes associated with HIV-infection.
PRESENTER(S):
Click the plus sign to see more detailed information about each speaker.
Dr. McNicholl is a Clinical Pharmacy Specialist with the Department of Medicine/UCSF Positive Health Practice and an Assistant Clinical Professor with the UCSF School of Pharmacy. Board certified in Pharmacotherapy with Added Qualifications in Infectious Diseases, Dr. McNicholl has held faculty appointments and/or had clinical practices at the University of Illinois-Chicago, University of Colorado, Kaiser Permanente, St. Louis College of Pharmacy, St. Louis VAMC and Barnes-Jewish Hospital/Clinics.
His primary focus is maintaining a clinical practice at the UCSF Positive Health Practice at San Francisco General Hospital where the clinic provides comprehensive healthcare for over 3,000 HIV positive patients. Other major responsibilities include managing a pharmacist staffed Adherence Support Program and serving on the Editorial Board, UCSF Center for HIV Information.
Kathleen Melbourne, PharmD, Associate Director, Medical Scientist, Gilead Sciences
Dr. Melbourne is an Associate Director and HIV Medical Scientist (covering Northeast US) at Gilead Sciences. She began her employment with Gilead Sciences in May 2006. She has been on the faculty of the University of Rhode Island College of Pharmacy since 1998, where she is currently a Clinical Associate Professor of Pharmacy. Dr. Melbourne received her BS and PharmD from the University of Rhode Island College of Pharmacy in 1993 and 1995, respectively. She completed an ASHP-accredited Pharmacy Practice Residency at the University of Pittsburgh Medical Center in 1996. In 1997, she completed an Infectious Disease/HIV Pharmacotherapy Fellowship at the Anti-infective Pharmacology Research Unit, affiliated with the University of Rhode Island College of Pharmacy and Brown University Medical School. From 1997-2006, Dr. Melbourne was the Director of the Pharmacy Care Management Program at Coastal Medical, a private medical group consisting of 16 physicians offices located throughout Rhode Island. During her tenure at Coastal Medical, Dr. Melbourne led the implementation of collaborative pharmacy services throughout the primary care network of Coastal Medical, directed a Pharmacy Residency Program, conducted clinical studies measuring the impact of clinical pharmacy services on patient outcomes, precepted PharmD students from the URI College of Pharmacy, and carried on a clinical practice involving both HIV-infected patients and patients with multiple chronic illnesses. Dr. Melbourne's work at Coastal Medical was recognized in 2000 by the American Pharmacists Association Foundation's Quality Center. Currently, her research and clinical focus is on the metabolic and morphologic changes associated with HIV-infection.
Describe the relationship between combination antiretroviral therapy and cardiovascular disease in HIV infected patients.
Develop an antiretroviral pharmacotherapy plan for an HIV infected patient with co-morbid conditions such as cardiovascular disease or hepatitis.
Discuss the current treatment guidelines for the management of hepatitis B and hepatitis C in the HIV infected patient.
Review the epidemiology of cardiovascular disease in the HIV-infected population.